전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved10 programs
AntibodyLimited DatastaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancerBTC+2
Trials 42Status Recruiting
CGTLimited DatastaleNational University Hospital, S…Phase 1

Interleukin, NK cells (Interleukin, NK cells)

Metastatic Nasopharyngeal · Metastatic Nasopharyngeal

#MetastaticNasopharyngeal#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 30Status Active
ADCLimited DatastaleLepu Medical Technology (Beijin…Phase 3

Becotatug Vedotin (Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Adenoid Cystic Carcinoma

#AdenoidCysticCarcinoma#ADC#Phase3#antibody-drug-conjugate#NasopharyngealCancinomaNPC+1
Trials 28Status Recruiting
ADCLimited DatastaleLepu Biopharma Co., Ltd.Phase 2

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

Hypopharyngeal Squamous Cell Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase2#antibody-drug-conjugate#HypopharyngealSquamousCellCarcin+1
Trials 11Status Recruiting
ADCLimited DatastaleSun Yat-sen UniversityPhase 3

Anti-PD1 combined with Becotatug Vedotin (Anti-PD1 combined with Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase3#antibody-drug-conjugate#Sun
Trials 1Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

cetuximab (C225, C225 (cetuximab))

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Active
CGTLimited DatastaleFujian Cancer HospitalPhase 2

EBV-TCR-T (YT-E001, EBV-TCR-T, EBV-TCR-T (YT-E001) cells)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleTCRCure Biopharma Ltd.Phase 2

EBV-specific TCR-T cell with cytokine auto-secreting element (EBV-specific TCR-T cell with cytokine auto-secreting element)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleSeoul National University Hospi…Phase 2

nivolumab (Opdivo, Gemcitabine+ nivolumab)

Recurrent or Metastatic Nasopharyngeal Carcinom · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#Antibody#Phase2#monoclonal-antibody#Seoul
Trials 1Status Active
CGTLimited DatastaleSun Yat-sen UniversityPhase 1

LMP2 Antigen-specific TCR T cells (LMP2 Antigen-specific TCR T cells)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active